These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36746984)

  • 1. Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study.
    Hou Y; Wang L; Li Y; Ai J; Tian L
    Sci Rep; 2023 Feb; 13(1):2127. PubMed ID: 36746984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.
    Guo Y; Liu S; Hu S; Li F; Jin L
    Front Endocrinol (Lausanne); 2021; 12():673284. PubMed ID: 34122349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cumulative live birth rate and perinatal outcomes in young patients with low anti-müllerian hormone levels using two ovulation promotion protocols: A cohort study.
    Li Z; Jia R; Wang K; Zhang J; Ren B; Guan Y
    Front Endocrinol (Lausanne); 2022; 13():938500. PubMed ID: 35992097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVF outcomes of women with discrepancies between age and serum anti-Müllerian hormone levels.
    Zhang B; Meng Y; Jiang X; Liu C; Zhang H; Cui L; Chen ZJ
    Reprod Biol Endocrinol; 2019 Jul; 17(1):58. PubMed ID: 31311571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment.
    Peuranpää P; Hautamäki H; Halttunen-Nieminen M; Hydén-Granskog C; Tiitinen A
    Hum Reprod; 2020 Mar; 35(3):504-515. PubMed ID: 32219343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization.
    Hamdine O; Eijkemans MJC; Lentjes EGW; Torrance HL; Macklon NS; Fauser BCJM; Broekmans FJ
    Fertil Steril; 2015 Oct; 104(4):891-898.e2. PubMed ID: 26196233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of cumulative outcomes and influencing factors of patients with discrepancies between age and AMH levels in the early follicular phase prolonged protocol.
    Wang K; Guan Y; Zhang Y; Jia R; Wu S; Yao Z; Zhang M; Li Z
    Front Endocrinol (Lausanne); 2023; 14():1098131. PubMed ID: 36967754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Müllerian hormone is a predictor of medium-term cumulative live birth following in vitro fertilization/intracytoplasmic sperm injection: A retrospective study.
    Kien Nguyen D; O'Leary S; Abdelhafez Gadalla M; Roberts B; Alvino H; Tremellen KP
    Eur J Obstet Gynecol Reprod Biol; 2022 May; 272():220-225. PubMed ID: 35395615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of anti-Mullerian hormone for pregnancy outcomes following assisted reproductive techniques (ART) in Southwest China.
    Liu L; Sun XY; Yang H; Feng XJ; Lan YZ
    Reprod Health; 2022 Dec; 19(1):224. PubMed ID: 36514055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients.
    Guo Y; Jiang H; Hu S; Liu S; Li F; Jin L
    J Ovarian Res; 2021 Aug; 14(1):111. PubMed ID: 34454544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study.
    Zhang S; Yin Y; Li Q; Zhang C
    Front Endocrinol (Lausanne); 2021; 12():644456. PubMed ID: 34234739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment?
    Lee Y; Kim TH; Park JK; Eum JH; Lee HJ; Kim J; Lyu SW; Kim YS; Lee WS; Yoon TK
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():151-155. PubMed ID: 29306180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum anti-Müllerian hormone and other factors with cumulative live birth rate following IVF.
    Hu KL; Liu FT; Xu H; Li R; Qiao J
    Reprod Biomed Online; 2020 May; 40(5):675-683. PubMed ID: 32268980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters.
    De Vos M; Pareyn S; Drakopoulos P; Raimundo JM; Anckaert E; Santos-Ribeiro S; Polyzos NP; Tournaye H; Blockeel C
    Reprod Biomed Online; 2018 Aug; 37(2):163-171. PubMed ID: 29778554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestin-Primed Ovarian Stimulation Versus Mild Stimulation Protocol in Advanced Age Women With Diminished Ovarian Reserve Undergoing Their First
    Tu X; You B; Jing M; Lin C; Zhang R
    Front Endocrinol (Lausanne); 2021; 12():801026. PubMed ID: 35140685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
    Yang C; Dong N; Li F; Ji Y; Pan Y; She H
    J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment.
    Sun TC; Zhou SJ; Song LL; Li JH; Chen X; Tian L
    JBRA Assist Reprod; 2021 Apr; 25(2):266-271. PubMed ID: 33710839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.